4‐O‐methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21‐mediated suppression of NF‐κB activity. (20th February 2013)
- Record Type:
- Journal Article
- Title:
- 4‐O‐methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21‐mediated suppression of NF‐κB activity. (20th February 2013)
- Main Title:
- 4‐O‐methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21‐mediated suppression of NF‐κB activity
- Authors:
- Lee, NJ
Oh, JH
Ban, JO
Shim, JH
Lee, HP
Jung, JK
Ahn, BW
Yoon, DY
Han, SB
Ham, YW
Hong, JT - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bph2235-sec-0001" sec-type="section"> <title>Background and Purpose</title> <p>The effects of 4‐<italic>O</italic>‐methylhonokiol (MH), a constituent of <italic>Magnolia officinalis</italic>, were investigated on human prostate cancer cells and its mechanism of action elucidated.</p> </sec> <sec id="bph2235-sec-0002" sec-type="section"> <title>Experimental Approach</title> <p>The anti‐cancer effects of MH were examined in prostate cancer and normal cells. The effects were validated <italic>in vivo</italic> using a mouse xenograft model.</p> </sec> <sec id="bph2235-sec-0003" sec-type="section"> <title>Key Results</title> <p>MH increased the expression of PPARγ in prostate PC‐3 and LNCap cells. The pull‐down assay and molecular docking study indicated that MH directly binds to PPARγ. MH also increased transcriptional activity of PPARγ but decreased NF‐κB activity. MH inhibited the growth of human prostate cancer cells, an effect attenuated by the PPARγ antagonist GW9662. MH induced apoptotic cell death and this was related to G<sub>0</sub>‐G<sub>1</sub> phase cell cycle arrest. MH increased the expression of the cell cycle regulator p21, and apoptotic proteins, whereas it decreased phosphorylation of Rb and anti‐apoptotic proteins. Transfection of PC3 cells with p21 siRNA or a p21 mutant plasmid on the cyclin D1/ cycline‐dependent kinase 4 binding site abolished the effects of MH on<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bph2235-sec-0001" sec-type="section"> <title>Background and Purpose</title> <p>The effects of 4‐<italic>O</italic>‐methylhonokiol (MH), a constituent of <italic>Magnolia officinalis</italic>, were investigated on human prostate cancer cells and its mechanism of action elucidated.</p> </sec> <sec id="bph2235-sec-0002" sec-type="section"> <title>Experimental Approach</title> <p>The anti‐cancer effects of MH were examined in prostate cancer and normal cells. The effects were validated <italic>in vivo</italic> using a mouse xenograft model.</p> </sec> <sec id="bph2235-sec-0003" sec-type="section"> <title>Key Results</title> <p>MH increased the expression of PPARγ in prostate PC‐3 and LNCap cells. The pull‐down assay and molecular docking study indicated that MH directly binds to PPARγ. MH also increased transcriptional activity of PPARγ but decreased NF‐κB activity. MH inhibited the growth of human prostate cancer cells, an effect attenuated by the PPARγ antagonist GW9662. MH induced apoptotic cell death and this was related to G<sub>0</sub>‐G<sub>1</sub> phase cell cycle arrest. MH increased the expression of the cell cycle regulator p21, and apoptotic proteins, whereas it decreased phosphorylation of Rb and anti‐apoptotic proteins. Transfection of PC3 cells with p21 siRNA or a p21 mutant plasmid on the cyclin D1/ cycline‐dependent kinase 4 binding site abolished the effects of MH on cell growth, cell viability and related protein expression. In the animal studies, MH inhibited tumour growth, NF‐κB activity and expression of anti‐apoptotic proteins, whereas it increased the transcriptional activity and expression of PPARγ, and the expression of apoptotic proteins and p21 in tumour tissues.</p> </sec> <sec id="bph2235-sec-0004" sec-type="section"> <title>Conclusions and Implication</title> <p>MH inhibits growth of human prostate cancer cells through activation of PPARγ, suppression of NF‐κB and arrest of the cell cycle. Thus, MH might be a useful tool for treatment of prostate cancer.</p> </sec> </abstract> … (more)
- Is Part Of:
- British journal of pharmacology. Volume 168:Number 5(2013:Mar.)
- Journal:
- British journal of pharmacology
- Issue:
- Volume 168:Number 5(2013:Mar.)
- Issue Display:
- Volume 168, Issue 5 (2013)
- Year:
- 2013
- Volume:
- 168
- Issue:
- 5
- Issue Sort Value:
- 2013-0168-0005-0000
- Page Start:
- 1133
- Page End:
- 1145
- Publication Date:
- 2013-02-20
- Subjects:
- Pharmacology -- Periodicals
Chemotherapy -- Periodicals
Drug Therapy -- Periodicals
Pharmacology -- Periodicals
615.1 - Journal URLs:
- http://bibpurl.oclc.org/web/21844 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381/issues ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=282&action=archive ↗
http://onlinelibrary.wiley.com/ ↗
http://www.nature.com/bjp/index.html ↗ - DOI:
- 10.1111/j.1476-5381.2012.02235.x ↗
- Languages:
- English
- ISSNs:
- 0007-1188
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2314.700000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3484.xml